{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:05:49Z","timestamp":1756382749107,"version":"3.38.0"},"reference-count":34,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Cutaneous T-cell lymphomas are a heterogeneous group of non-Hodgkin lymphomas. Early stages are often controlled with skin-directed therapy, such as topical corticosteroids, topical chlormethine gel, or UV therapy, whereas advanced stages often warrant a more aggressive approach with systemic antibody targeted therapy including mogamulizumab, brentuximab vedotin, or alemtuzumab. A retrospective cohort case series of 27 patients from Aarhus University Hospital, Denmark is presented, evaluating real-world outcomes of patients with cutaneous T-cell lymphomas treated with intravenous systemic targeted therapies from 2013 to 2023. The median age was 72 and the majority had S\u00e9zary syndrome or mycosis fungoides. All patients had relapsed\/refractory advanced stage cutaneous T-cell lymphoma. Six patients received mogamulizumab, 12 patients received brentuximab vedotin, and 15 patients received alemtuzumab. Six patients received more than 1 of the systemic targeted treatments. Overall response rates were 78% for mogamulizumab, 65% for brentuximab vedotin, and 61% for alemtuzumab. Median time to progression was 2.5, 4, and 11 months, respectively. In conclusion, this paper offers a unique perspective on the complexities of clinical practice when managing advanced-stage cutaneous T-cell lymphomas and demonstrates the effectiveness of the therapies described, with particular emphasis on the promising results observed with alemtuzumab administered in a low-dose protocol.<\/jats:p>","DOI":"10.2340\/actadv.v105.40952","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T14:05:08Z","timestamp":1741874708000},"page":"adv40952","source":"Crossref","is-referenced-by-count":1,"title":["Systemic Targeted Therapies in Patients with Relapsed\/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series"],"prefix":"10.2340","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2481-035X","authenticated-orcid":false,"given":"Signe","family":"Hedebo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-2374","authenticated-orcid":false,"given":"Martin B.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise M.","family":"Lindahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aska","family":"Drjlevic-Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-5127","authenticated-orcid":false,"given":"Claus","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4032-6633","authenticated-orcid":false,"given":"Francesco","family":"D'Amore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1816-4508","authenticated-orcid":false,"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikke","family":"Bech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"103170","doi-asserted-by":"crossref","unstructured":"Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730\u20134739.","DOI":"10.1200\/JCO.2009.27.7665"},{"key":"103171","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2009.27.7665","DOI":"10.1200\/JCO.2009.27.7665"},{"key":"103172","doi-asserted-by":"crossref","unstructured":"Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: final data. Blood Adv 2021; 5: 5098\u20135106.","DOI":"10.1182\/bloodadvances.2021004710"},{"key":"103173","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004710","DOI":"10.1182\/bloodadvances.2021004710"},{"key":"103174","doi-asserted-by":"crossref","unstructured":"Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1192\u20131204.","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"103175","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(18)30379-6","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"103176","doi-asserted-by":"crossref","unstructured":"Fujimura T, Amagai R, Kambayashi Y, Aiba S. Topical and systemic formulation options for cutaneous T cell lymphomas. Pharmaceutics 2021; 13.","DOI":"10.3390\/pharmaceutics13020200"},{"key":"103177","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/pharmaceutics13020200","DOI":"10.3390\/pharmaceutics13020200"},{"key":"103178","doi-asserted-by":"crossref","unstructured":"Muniesa C, Gallardo F, Garc\u00eda-Doval I, Estrach MT, Combalia A, Morillo-And\u00fajar M, et al. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry. J Eur Acad Dermatol Venereol 2023; 37: 57\u201364.","DOI":"10.1111\/jdv.18563"},{"key":"103179","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.18563","DOI":"10.1111\/jdv.18563"},{"key":"103180","doi-asserted-by":"crossref","unstructured":"Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 2012; 4: 117ra117.","DOI":"10.1126\/scitranslmed.3003008"},{"key":"103181","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1126\/scitranslmed.3003008","DOI":"10.1126\/scitranslmed.3003008"},{"key":"103182","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Corradini P, Gallamini A, Grossi A, Lazzarino M, Marchetti M, et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma 2012; 53: 789\u2013795.","DOI":"10.3109\/10428194.2011.629701"},{"key":"103183","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/10428194.2011.629701","DOI":"10.3109\/10428194.2011.629701"},{"key":"103184","doi-asserted-by":"crossref","unstructured":"Weaver TA, Kirk AD. Alemtuzumab. Transplantation 2007; 84: 1545\u20131547.","DOI":"10.1097\/01.tp.0000296680.75175.67"},{"key":"103185","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/01.tp.0000296680.75175.67","DOI":"10.1097\/01.tp.0000296680.75175.67"},{"key":"103186","doi-asserted-by":"crossref","unstructured":"Ravandi F, O\u2019Brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest 2006; 24: 718\u2013725.","DOI":"10.1080\/07357900600981414"},{"key":"103187","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/07357900600981414","DOI":"10.1080\/07357900600981414"},{"key":"103188","doi-asserted-by":"crossref","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703\u20131714.","DOI":"10.1182\/blood-2018-11-881268"},{"key":"103189","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2018-11-881268","DOI":"10.1182\/blood-2018-11-881268"},{"key":"103190","doi-asserted-by":"crossref","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713\u20131722.","DOI":"10.1182\/blood-2007-03-055749"},{"key":"103191","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2007-03-055749","DOI":"10.1182\/blood-2007-03-055749"},{"key":"103192","doi-asserted-by":"crossref","unstructured":"Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479\u2013484.","DOI":"10.1182\/blood-2006-10-054601"},{"key":"103193","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2006-10-054601","DOI":"10.1182\/blood-2006-10-054601"},{"key":"103194","doi-asserted-by":"crossref","unstructured":"Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022; 140: 419\u2013437.","DOI":"10.1182\/blood.2021012057"},{"key":"103195","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood.2021012057","DOI":"10.1182\/blood.2021012057"},{"key":"103196","doi-asserted-by":"crossref","unstructured":"Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, et al. Effectiveness of mogamulizumab in patients with mycosis fungoides or S\u00e9zary syndrome: a multicentre, retrospective, real-world French study. J Eur Acad Dermatol Venereol 2023; 37: 1777\u20131784.","DOI":"10.1111\/jdv.19134"},{"key":"103197","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.19134","DOI":"10.1111\/jdv.19134"},{"key":"103198","doi-asserted-by":"crossref","unstructured":"de Masson A, Guitera P, Brice P, Moulonguet I, Mouly F, Bouaziz JD, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol 2014; 170: 720\u2013724.","DOI":"10.1111\/bjd.12690"},{"key":"103199","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.12690","DOI":"10.1111\/bjd.12690"},{"key":"103200","doi-asserted-by":"crossref","unstructured":"Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides\/S\u00e9zary syndrome: a retrospective cohort study. Br J Dermatol 2018; 179: 1322\u20131328.","DOI":"10.1111\/bjd.17073"},{"key":"103201","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.17073","DOI":"10.1111\/bjd.17073"},{"key":"103202","doi-asserted-by":"crossref","unstructured":"Scarisbrick JJ. Infections in mycosis fungoides and S\u00e9zary syndrome are a frequent cause of morbidity and contribute to mortality. What can be done? Br J Dermatol 2018; 179: 1243\u20131244.","DOI":"10.1111\/bjd.17194"},{"key":"103203","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.17194","DOI":"10.1111\/bjd.17194"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/40952\/49517","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/40952\/49517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T14:05:30Z","timestamp":1741874730000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/40952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":34,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.40952","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}